Sio Gene Therapies Inc. is a clinical-stage company. The Company is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The Company is primarily focused on pre-clinical research and development initiatives in gene therapy.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)